Rocket Secures $150M Credit Facility from Hercules Capital, Extending Cash Runway
RCKT is trading near its 52-week low of $2.46 (0.8% above the low).
Summary
Rocket Pharmaceuticals closed a credit facility with Hercules Capital for up to $150 million, receiving $35 million upfront. The staged structure includes $20 million Tranche 1-B and $15 million Tranche 1-C available through 2027, $30 million tied to a Danon disease clinical milestone, and $50 million subject to Hercules' approval. The facility carries a 30-month interest-only period and 48-month maturity, with warrants for 1,755,853 shares at $2.99, 409,699 exercisable after initial draw. Management says the initial draw extends cash runway into Q3 2028, with potential to reach 2029 if further tranches are drawn. This follows the company's recent FDA alignment on the pivotal Phase 2 Danon trial and provides non-dilutive capital to fund the study. Hercules Capital (HTGC) is the lender, but the primary impact is on Rocket's balance sheet and execution risk.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The 8-K details the facility: $35M Tranche 1-A funded, $20M Tranche 1-B and $15M Tranche 1-C available through 2027, $30M Tranche 2 upon Danon milestone, $50M Tranche 3 subject to approval; warrants for 1,755,853 shares at $2.99, 409,699 exercisable after initial draw.
At the time of this announcement, RCKT was trading at $2.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $272.2M. The 52-week trading range was $2.46 to $5.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.